Clinical Trial: NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-02-06 |
Study Overview
Brief Summary
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
Official Title
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Conditions
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
Intervention / Treatment
- Drug: LOXO-305
Other Study ID Numbers
- 17746
- J2N-MC-JZNJ
Start Date (Actual)
2021-05-14
Primary Completion Date (Actual)
2023-04-10
Study Completion Date (Actual)
2025-12-29
Enrollment (Actual)
87
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-02-06 |
Study Overview
Brief Summary
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
Official Title
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Conditions
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
Intervention / Treatment
- Drug: LOXO-305
Other Study ID Numbers
- 17746
- J2N-MC-JZNJ
Start Date (Actual)
2021-05-14
Primary Completion Date (Actual)
2023-04-10
Study Completion Date (Actual)
2025-12-29
Enrollment (Actual)
87
Study Type
Interventional
Phase
Phase 2